# Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

> **NCT04845399** · PHASE3 · COMPLETED · sponsor: **Zhengzhou Gensciences Inc** · enrollment: 101 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

## Key facts

- **NCT ID:** NCT04845399
- **Lead sponsor:** Zhengzhou Gensciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-16
- **Primary completion:** 2021-06-26
- **Final completion:** 2021-06-26
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04845399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04845399, "Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04845399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*